Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models

Prostate

Volumn 72, Issue 14, 2012, Pages 1542-1549

  Ateeq, Bushra ^a   Vellaichamy, Adaikkalam ^a   Tomlins, Scott A ^a   Wang, Rui ^a   Cao, Qi ^a   Lonigro, Robert J ^a   Pienta, Kenneth J ^a   Varambally, Sooryanarayana ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

5 reductase; dutasteride; gene fusion; prostate cancer; TMPRSS2 ERG

Indexed keywords

ANDROSTANOLONE; BICALUTAMIDE; DUTASTERIDE; STEROID 5ALPHA REDUCTASE 1; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

5-ALPHA REDUCTASE INHIBITORS; ANIMALS; AZASTEROIDS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865471699     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22509     Document Type: Article

References (24)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648;. (Pubitemid 41528150)
2. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM,. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448 (7153): 595-599;. (Pubitemid 47206938)
3. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM,. Recurrent gene fusions in prostate cancer. Nat Rev 2008; 8 (7): 497-511;.
4. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM,. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10 (2): 177-188;. (Pubitemid 351240884)
5. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S,. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27 (40): 5348-5353;.
6. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V,. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105 (6): 2105-2110;. (Pubitemid 351439472)
7. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL,. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41 (5): 524-526;.
8. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM,. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17 (5): 443-454;.
9. Gillatt D,. Antiandrogen treatments in locally advanced prostate cancer: Are they all the same ? J Cancer Res Clin Oncol 2006; 132 (Suppl 1): S17-S26;. (Pubitemid 46360130)
10. Ang JE, Olmos D, de Bono JS,. CYP17 blockade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009; 100 (5): 671-675;.
11. Nacusi LP, Tindall DJ,. Targeting 5alpha-reductase for prostate cancer prevention and treatment. Nat Rev Urol 2011; 8 (7): 378-384;.
12. Bartsch G, Rittmaster RS, Klocker H,. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002; 19 (6): 413-425;.
13. Tindall DJ, Rittmaster RS,. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008; 179 (4): 1235-1242;.
14. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H,. Novel 5alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008; 99 (1): 81-86;. (Pubitemid 350239034)
15. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N,. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108 (33): 13728-13733;.
16. Olsson Gisleskog P, Hermann D, Hammarlund-Udenaes M, Karlsson MO,. Validation of a population pharmacokinetic/pharmacodynamic model for 5alpha-reductase inhibitors. Eur J Pharm Sci 1999; 8 (4): 291-299;. (Pubitemid 29325021)
17. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS,. Dutasteride in localised prostate cancer management: The REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012; [Epub ahead of print].
18. Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD, Nelson PS,. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: Implications for prostate cancer chemoprevention. Cancer Res 2010; 70 (4): 1286-1295;.
19. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM,. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100 (20): 11606-11611;. (Pubitemid 37205983)
20. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM,. TMPRS S2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66 (7): 3396-3400;.
21. Barqawi AB, O'Donnell CI, Siomos VJ, Hou AH,. The effect of short-term dutasteride intake in early-stage prostate cancer: Analysis of 148 patients who underwent three-dimensional prostate mapping biopsy. Urology 2010; 76 (5): 1067-1071;.
22. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS,. Effect of dutasteride on the risk of prostate cancer. New Engl J Med 2010; 362 (13): 1192-1202;.
23. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP,. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15 (22): 7099-7105;.
24. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324 (5928): 787-790;.